Dupilumab given concomitantly with topical corticosteroids significantly improved signs and symptoms of atopic dermatitis (AD) in adults refractory to or intolerant of cyclosporine A, a study shows.
Dermatology Times – Dermatology
Tag Archives: Dupilumab
Mar 15, Sanofi’s Dupilumab Joins UK’s Early Access Scheme
Patients with atopic dermatitis are to get early access to Sanofi’s dupilumab before it is given marketing authorisation in the UK. This is after some positive research results were received from testing. It will be available to adult patients who have severe atopic dermatitis that has not responded to, or are unable to use, other treatments.
Eczema Blog
EU approves Sanofi and Regeneron’s dupilumab in eczema – Reuters
Reuters |
EU approves Sanofi and Regeneron's dupilumab in eczema
Reuters Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, and often unbearable, itching. A human monoclonal antibody, Dupixent is designed to specifically inhibit two key proteins which are … Sanofi's Dupixent gets Europe eczema nod Sanofi, Regeneron claim EU approval for eczema drug Dupixent Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to … |
Mar 15, Sanofi’s Dupilumab Joins UK’s Early Access Scheme
Patients with atopic dermatitis are to get early access to Sanofi’s dupilumab before it is given marketing authorisation in the UK. This is after some positive research results were received from testing. It will be available to adult patients who have severe atopic dermatitis that has not responded to, or are unable to use, other treatments.
Eczema Blog